Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus FOAMICON.
ANUSOL HC vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid